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SObjective: In patients with esophageal cancer, a complete pathologic response after preoperative therapy is uni-
versally regarded as a favorable prognostic factor. However, less is known about factors predictive of outcome in
patients with persistent nodal disease. The purpose of this study is to determine which variables affect survival in
this patient population.
Methods: We reviewed a prospectively maintained esophageal cancer database. Patients with positive lymph no-
des after preoperative therapy and surgery were selected. Predictors of survival were examined univariately using
the log–rank test. Factors identified at P<.20 by univariate analysis were selected for inclusion in a multivariate
model.
Results: Ninety-six patients with 1 or more positive nodes received preoperative therapy. Pathologic T classifi-
cation was 0 to 2 in 25 (26%) patients and 3 to 4 in 71 (74%) patients. In 29 (30%) patients, nonregional nodal
disease was present (M1). Final pathologic stages were IIB in 18 (19%), III in 49 (51%), and IV in 29 (30%).
Postoperatively, 44 (46%) patients received additional chemotherapy. On univariate analysis, pathologic stage,
pathologic T classification, and number of positive nodes significantly affected overall survival. On multivariate
analysis, clinical stage (hazard ratio [HR], 2.25; P ¼ .05), pathologic T classification (HR, 3.06; P ¼ .006), and
number of positive nodes (HR 1.03 per node, P ¼ .09) were significant predictors of overall survival.
Conclusion: Long-term survival can be achieved in patients with esophageal cancer who have persistent nodal
disease after neoadjuvant therapy and surgical resection. Clinical stage, pathologic T classification, and num-
ber of positive nodes best predict survival. Nonregional nodal disease does not adversely affect outcome. Post-
operative chemotherapy conferred no additional survival benefit in this patient population. (J Thorac
Cardiovasc Surg 2010;139:387-94)Locally advanced esophageal cancer is associated with an
extremely poor prognosis. Neoadjuvant chemotherapy or
combined chemoradiation is commonly used in the treat-
ment of this disease. A recent meta-analysis of randomized
trials demonstrated survival benefits after either neoadjuvant
chemoradiotherapy or neoadjuvant chemotherapy.1 It is gen-
erally recognized that patients with a complete pathologic
response (pCR) after neoadjuvant therapy have significantly
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The Journal of Thoracic and CaUnfortunately, pCR is typically achieved in only 3% to 5%
of patients who receive neoadjuvant chemotherapy alone
and in 16% to 51% of patients who receive neoadjuvant
chemoradiation.8 The purpose of this study is to determine
which variables affect survival in a population of patients
with esophageal cancer who have persistent nodal metasta-
ses after neoadjuvant chemotherapy and surgery.METHODS
Study Design
This is a retrospective review of a prospectively assembled thoracic sur-
gery database. The Institutional Review Board of Weill Medical College
and the New York–Presbyterian Hospital approved the database and the
study design. Patient consent was waived. Patients were eligible for this re-
view if they had pathologically confirmed squamous cell carcinoma or ad-
enocarcinoma of the tubular esophagus or gastroesophageal junction
(Siewert type I or II) and were treated by neoadjuvant therapy followed
by esophagectomy and had persistent nodal metastases in the resected spec-
imen. Between April 1994 and July 2008, 96 patients fulfilled these selec-
tion criteria. Preoperative evaluation included an upper endoscopy with
biopsy and a computerized tomogram of the chest and upper abdomen in
all cases. A majority of patients also had endoscopic ultrasonography and
positron emission tomography (PET). Patients with Eastern Cooperative
Oncology Group (ECOG) performance status 0/1 who had clinical stage
II or higher disease were given induction therapy followed by surgical resec-
tion. Although our institutional policy is to administer preoperative chemo-
therapy without radiation therapy for patients with locally advanced disease,rdiovascular Surgery c Volume 139, Number 2 387
TABLE 1. Clinical and pathologic characteristics of patients with
positive lymph nodes after neoadjuvant chemotherapy and surgical
resection
Parameter No. (%) of patients
Age (y)
Median 62
Range 24–84
Gender
Male 82 (85%)
Female 14 (15%)
Clinical stage
I 1 (1%)
II 19 (20%)
III 52 (61%)
IV 13 (15%)
Histology
Adenocarcinoma 73 (76%)
Squamous cell carcinoma 23 (24%)
Location
Upper 6 (6%)
Middle 12 (13%)
Lower 62 (65%)
Gastroesophageal junction 16 (17%)
pT classification
T0 4 (4%)
T1 4 (4%)
T2 17 (18%)
T3 68 (71%)
T4 3 (3%)
Median lymph nodes resected
No. 33
Range 6–84
Median metastatic lymph nodes
No. 4
Range 1–31
M status
M0 67 (70%)
M1a 9 (9%)
M1b 20 (21%)
Pathologic stage
IIB 18 (19%)
III 49 (51%)
IVA 9 (9%)
IVB 20 (21%)
Abbreviations and Acronyms
CI ¼ confidence interval
HR ¼ hazard ratio
pCR ¼ complete pathologic response
PET ¼ positron emission tomography
pT ¼ pathologic T
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Spatients receiving preoperative chemoradiation therapy were not excluded
from this study. After induction therapy, all patients underwent the planned
surgical resection unless systemic metastases were demonstrated on restag-
ing scans after neoadjuvant therapy or if they had a significant deterioration
in their general medical condition that precluded operation. Patients with
persistent nodal disease or local disease progression were not excluded
from the planned operation. All demographic, staging, surgical, periopera-
tive, and survival data were reviewed.
Surgical Treatment
The majority of the patients underwent a transthoracic en bloc resection
with either a 2-field (mediastinal and abdominal nodes) or a 3-field (medi-
astinal, abdominal, and cervical) dissection. The technique of en bloc resec-
tion was described previously and includes resection of the tumor-bearing
esophagus along with the thoracic duct, both pleural surfaces, and all lymph
nodes in the middle and lower mediastinum, including the periesophageal,
parahiatal, subcarinal, and aortopulmonary nodes.9 In the abdomen, an
upper abdominal and retroperitoneal node dissection was performed includ-
ing the celiac, splenic, common hepatic, left gastric, lesser curvature, and
parahiatal nodes. For the cervical dissection (3-field), the right and left
recurrent laryngeal nodes were also dissected. Alternatively, resection
was done by either a non–en bloc conventional transthoracic approach or
a transhiatal approach. During these procedures, the esophagus was resected
along with the periesophageal, perigastric, and left gastric nodes. Celiac
nodes were also excised if they were pathologically enlarged.
Follow-up
The majority of patients were personally examined and interviewed by
the operating surgeons every 3 months for the first 2 years and every 6
months thereafter. Patients from distant geographic locations were moni-
tored by contacting their treating physician and/or by direct telephone con-
tact. A computed tomographic scan of the chest and upper abdomen was
done at 6 and 12 months postoperatively and subsequently on an annual ba-
sis. All data were collected, entered into a prospective database, and updated
at regular intervals. Complete follow-up information until death or October
2008 was available for all patients.
Statistical Analysis
The database was queried to identify relevant clinical and pathologic
characteristics. The primary end point was overall survival, determined
by the Kaplan–Meier method. The 2- and 5-year overall survival estimates
are reported along with 95% confidence intervals (CI) for the survival esti-
mates. Overall survival was defined as the time from date of surgery until the
date of death or date of last follow-up if alive. Disease-free survival was de-
fined from the date of surgery until date of documented disease recurrence.
Predictors of survival were examined univariately using the log–rank test.
Small subgroups within clinical stage and pathologic T (pT) classification
were collapsed owing to sample size concerns. Total number of lymph no-
des removed and number of pathologically positive lymph nodes were ex-
amined as categorical variables based on quartiles. Factors identified at P<
.20 by univariate analysis were selected for inclusion in a multivariate Cox
proportional hazards regression model. All P values are 2-sided with statis-388 The Journal of Thoracic and Cardiovascular Surgtical significance evaluated at the .05 alpha level, and 95% CIs were calcu-
lated to assess the precision of the obtained estimates. All analyses were
performed in SAS version 9.2 (SAS Institute, Inc, Cary, NC) and SPSS ver-
sion 17.0 (SPSS Inc, Chicago, Ill).RESULTS
Patients
Of 451 patients undergoing esophagectomy during the
time period of the study, 153 received neoadjuvant chemo-
therapy. Of these patients, 96 (63%) were found to have
one or more metastatic lymph nodes on pathologic review.
Clinical and pathologic characteristics are listed in Table 1.ery c February 2010
FIGURE 1. A, Overall survival for all patients with positive lymph nodes after neoadjuvant chemotherapy and surgical resection. B, Two-year overall sur-
vival stratified by pathologic stage (pStage).
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SOne (1%) patient with documented clinical stage I disease
was given neoadjuvant therapy by a referring oncologist.
Clinical stages of the remaining patients are documented
in Table 1. Eight (8%) patients did not have complete doc-
umentation of clinical stage. The majority of the patients
(91%) received 2 to 4 cycles of chemotherapy preopera-
tively. The most common chemotherapeutic agents given
were carboplatin (n ¼ 54, 56%), paclitaxel (Taxol) (n ¼
53, 55%), cisplatin (n ¼ 32, 33%), docetaxel (Taxotere)
(n ¼ 12, 13%), and 5-fluorouracil (n ¼ 11, 11%). In addi-
tion to neoadjuvant chemotherapy, 9 (9%) patients received
neoadjuvant radiation therapy, 7 patients concurrently and 2
patients sequentially. Data for assessment of clinicalThe Journal of Thoracic and Caresponse to neoadjuvant therapy were available in 65
(68%) patients. In these patients, clinical response was listed
as complete in 7 (11%), partial in 30 (46%), minimal in 3
(5%), and stable disease in 25 (38%).
Operation and Pathologic Staging
The majority of patients (n¼ 87, 91%) underwent radical
en bloc esophagectomy. Of these, 22 (23%) patients had
a 2-field lymph node dissection, and 65 (68%) patients had
a 3-field nodal dissection. The remaining 9 (9%) patients un-
derwent nonradical esophagectomy, either transthoracic or
transhiatal. Pathologic findings are listed in Table 1. Four
(4%) patients had no residual primary tumor and were thusrdiovascular Surgery c Volume 139, Number 2 389
TABLE 2. Univariate analysis of prognostic factors for overall
survival (OS)
Variable Subgroups Two-year OS (%) P value
Clinical stage I, II 62 .04
III, IV 43
Pathologic stage IIB 70 .01
III 31
IVA 75
IVB 46
pT status 0, 1, 2 74 .001
3, 4 35
Number of positive
nodes (by quartile)
1 58 .009
2–3 56
4–7 44
>7 19
Total nodes resected
(by quartile)
<22 40 .66
23–32 40
33–42 50
>42 43
pM status M0 42 .25
M1 55
Adjuvant chemotherapy No 41 .86
Yes 50
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Sclassified as T0. Remaining pT classifications are listed in
Table 1. The median number of lymph nodes resected was
33 (range, 6–84). Although all patients had at least one positive
lymph node, 29 (30%) patients were noted to have either recur-
rent laryngeal (n ¼ 24) or celiac axis nodes (n ¼ 5) and were
thus classified as having M1 disease. On the basis of the rela-
tionship to tumor location, 9 patients had M1a and 20 had
M1b disease. The median number of positive nodes was 4
(range 1–31). Final pathologic stages are listed in Table 1.Follow-up Treatment and Survival
After surgical resection, 44 (46%) patients received addi-
tional chemotherapy, the majority of whom (89%) received
just one more cycle. Median time of follow-up of all surviv-
ing patients was 35 months. Overall survival for the entire
cohort was 46% (95% CI, 35%–56%) at 2 years and
30% (95% CI, 20%–42%) at 5 years (Figure 1, A). Two-
year overall survival (Figure 1, B) for patients with stage II
disease was 70% (95%CI, 42%–86%), for stage III disease
31% (95% CI, 17%–45%), for stage IVA disease 75%
(95% CI, 31%–93%), and for stage IVB disease 46%
(95% CI, 23%–66%) (P¼ .01). For the entire cohort of pa-
tients with positive nodes after neoadjuvant chemotherapy,
disease-free survival was 41% (95% CI, 30%–52%) at 2
years and 24% (95% CI, 15%–35%) at 5 years.Recurrence
Of 55 (57%) patients with documented recurrences, 10
(10%) had only local recurrence (either in regional lymph390 The Journal of Thoracic and Cardiovascular Surgnodes or at the resection margin), 34 (35%) had only sys-
temic recurrence, and 11 (11%) had both local and systemic
recurrences.
Prognostic Factors
On univariate analysis, several variables predicting overall
survival were identified (Table 2). Pathologic stage, pT clas-
sification, and the number of positive nodes resected signifi-
cantly affected overall survival. The number of positive
nodes resected was examined both as a continuous variable
and by quartiles, recognizing that nodal count may be sub-
jected to incomplete counting or to interindividual variation.
Using binary cut points of 6 versus>6 nodes positive,
7 versus>7 nodes positive, 8 versus>8 nodes positive,
and 9 versus>9 nodes positive, all revealed near-identical,
statistically significant differences in overall survival between
the binary categories of each unique cut point. For patients
with 7 positive nodes versus patients with>7 positive no-
des, for example, 2-year overall survival was 54% (95%
CI, 41%–65%) versus 19% (95% CI, 6%–38%), respec-
tively (P ¼ .0012) (Figure 2). When examined in the same
manner, total number of lymph nodes resected was not signif-
icant (P ¼ .66; Table 2). Similarly, patient age, gender, and
histologic type had no effect on overall survival (P overall
survival ¼ .66, P ¼ .74, and P ¼ .79, respectively). A trend
toward improved 2-year overall survival on univariate analy-
sis was apparent in patients with earlier clinical stage (I–II, n
¼ 19) versus those with more advanced clinical stage (III–IV,
n¼ 69) (2-year overall survival¼ 62% vs 43%, respectively,
P¼ .04; Table 2). M1 status, administration of additional che-
motherapy, and the total number of lymph nodes resected did
not affect overall survival (Table 2). Postoperative chemo-
therapy also had no effect on disease-free survival (Table
2). Factors identified at P< .20 by univariate analysis for
overall survival were included in a multivariate Cox propor-
tional hazards regression model (Table 3). In this model, clin-
ical stage (hazard ratio [HR], 2.25; 95% CI, 1.001–5.06; P¼
.05), pT classification (HR, 3.06; 95% CI, 1.39–6.74; P ¼
.006), and number of positive nodes resected (HR, 1.03 per
node; 95% CI, 0.99–1.07; P ¼ .09) were significant predic-
tors or borderline significant predictors of overall survival.
Pathologic stage was not included in the final multivariate
model owing to strong colinearity with pT classification.
DISCUSSION
It is widely established that patients experiencing a pCR
after neoadjuvant therapy have a distinct survival advantage
over those who do not. Although the American Joint Com-
mittee for Cancer Staging TNM classification system does
not include a category for pCR, in most reported surgical
series patients are often grouped as to whether pCR is
achieved or not. Gu and associates10 reported 5-year overall
survivals of 56% for patients with pCR, compared with
25% in patients with residual tumors. Donahue andery c February 2010
FIGURE 2. Overall survival based on total number of positive lymph nodes resected.
TABLE 3. Multivariate analysis of prognostic factors for overall
survival
Variable HR CI P value
Clinical stage (III, IV vs IIB) 2.25 1.001–5.06 .05
pT status (3,4 vs 0–2) 3.06 1.39–6.74 .006
No. of positive nodes 1.03 per node 0.99–1.07 .09
HR, Hazard ratio; CI, confidence interval.
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overall survivals of 55% in patients with pCR and 26% in
patients with residual disease.
However, the survival benefit of neoadjuvant therapy for
the majority of patients, those who do not achieve a pCR, is
more difficult to elucidate. This is especially true for patients
with persistent nodal disease for whom factors predictive of
long-term survival have not been consistently described.6,7,10
Gu and associates10 suggested that the presence of more than
one metastatic lymph node was associated with worse 5-year
overall survival (6% vs 34% in patients with one positive
node). Rizk and associates6 also identified the presence of
more than one involved lymph node as a poor prognostic fac-
tor in a recursive partitioning model. However, there was only
a small incremental difference in 3-year overall survival com-
pared with patients with only one positive node (26% vs
32%). In the current series, we observed no difference in sur-
vival for up to 3 positive nodes. Only when 4 or more nodes
were positive was there a decrease in survival. By statistical
analysis, the best cut point for distinguishing groups by posi-
tive lymph nodes was between 6 and 9, significantly higher
than that reported in previous series.
Similarly, the presence of M1 disease may have important
implications regarding survival in patients with esophageal
cancer receiving neoadjuvant therapy. Several investigators
have recently reported that 5-year survival for stage IVa/IVb
disease after chemoradiation followed by esophagectomy is
less than 10%.6,11,12 These findings contrast significantly
with our cohort of patients with stage IVa or IVb disease.
Thirty percent (n ¼ 29) of our patients were found to have
M1 disease. The 2-year survival of this group was 55%The Journal of Thoracic and Caand the 5-year survival was 36%. Although there was a trend
toward improved survival in the patients with stage IVA dis-
ease versus stage IVB disease (75% vs 46%, 2-year overall
survival), the difference was not statistically significant (P¼
.117). The presence of M1 disease, therefore, seems to have
no effect on overall survival in this cohort of patients. In-
deed, Lee and associates13 recently reported that the 5-year
survival of all patients who underwent resection of esopha-
geal cancer and had nonregional nodal disease was 25%.
The reasons for the discrepancy between our results and
those reported in the literature are not entirely clear. Al-
though one cannot reasonably exclude patient selection
bias in any retrospective review, there is at least a reasonable
probability that differences in surgical strategy may account
for some of the results. For example, Rizzetto and col-
leagues14 have recently reported improved survival with
en bloc resection compared with transhiatal resection after
neoadjuvant therapy for esophageal cancer. In patients
with residual disease, they reported a 5-year overall survival
of 48% for en bloc resection, compared with 9% for tran-
shiatal resection. Likewise, our findings support an en bloc
surgical approach in patients with esophageal cancer after
neoadjuvant therapy. In the current report, over 90% ofrdiovascular Surgery c Volume 139, Number 2 391
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Spatients were treated with en bloc resection and either a 2- or
3-field lymphadenectomy. The median number of lymph no-
des resected was 33. This is nearly double the median num-
ber of lymph nodes resected in comparable surgical series
not using an en bloc approach.6,7,10 We15 have previously
reported that the total number of lymph nodes resected pre-
dicts survival in patients with esophageal cancer not treated
by neoadjuvant therapy. This effect is likely exerted in two
manners. When more lymph nodes are resected, there is
a stage migration toward higher pTNM stages. This results
in improved survival in the lower stages. Although all of
the patients in our series had positive lymph nodes, it is
likely that some of them would have been classified as N0
had a lesser lymph node dissection been performed. Simi-
larly, by often including the recurrent laryngeal chain in
our lymph node dissection (third field), we found a signifi-
cant number of patients with lower third or gastroesophageal
junction tumors with stage IVb disease. Indeed, 48% of our
patients with M1 disease had lower third or gastroesopha-
geal junction tumors with metastases to the recurrent laryn-
geal chain. These patients would have been understaged if
a 3-field lymph node resection had not been performed.
We also believe that the total number of lymph nodes re-
sected in and of itself may have a therapeutic benefit. We15
have previously reported that the total number of resected
nodes is a significant determinant of survival in node-posi-
tive patients treated by surgery alone. In comparison with
patients with 16 or fewer lymph nodes resected, there was
a 47%, 61%, and 51% statistically significant reduction
in the hazard ratio for death if 17 to 25, 26 to 40, and
more than 40 lymph nodes, respectively, were resected. Sim-
ilarly, recent reviews of the Surveillance, Epidemiology and
End Results database and of an international database de-
scribed increased survival with higher total negative lymph
node counts and higher total lymph node counts.16,17
Although we were unable to demonstrate significance of
the total number of lymph nodes resected in the current
study, this effect was almost certainly diluted by the high
median number of lymph nodes resected in 90% of patients.
The postoperative treatment options for patients with per-
sistent nodal disease after preoperative therapy and esopha-
gectomy are limited. Adjuvant therapy of any kind after
esophagectomy is notoriously poorly tolerated. A majority
of patients receive only a fraction of the prescribed treatment
regimen. The decision to offer patients postoperative ther-
apy, especially for patients with esophageal adenocarci-
noma, is further handicapped by the absence of supporting
evidence from randomized trials. However, there is some ev-
idence from retrospective case series that adjuvant therapy
may improve survival in carefully selected patients, particu-
larly those with lymph node metastases.18-20 However, these
studies were not performed in the context of patients who
also received neoadjuvant therapy. Indeed, little data exist
as to the relative benefit of adjuvant therapy in the popula-392 The Journal of Thoracic and Cardiovascular Surgtion of patients previously treated by neoadjuvant therapy
and surgical resection. In the current series, only 46% of pa-
tients received postoperative chemotherapy, typically only
one cycle. One cannot reasonably expect a survival benefit
to accrue to these patients given the suboptimal delivery of
chemotherapy. The inability of our patients to tolerate adju-
vant chemotherapy is consistent with evidence from ran-
domized trials comparing perioperative chemotherapy to
surgery alone. For example, in the recently reported MAGIC
trial, comparing preoperative followed by postoperative che-
motherapy to surgery alone, only 55% of the randomized
patients began postoperative chemotherapy and only 42%
completed treatment per protocol.21 The significant survival
benefit in the experimental arm of that trial was mainly at-
tributed to the preoperative rather than the postoperative
therapy component.
The strength of the current study is its focus on a homoge-
neous patient population that was nearly uniformly (>90%)
treated by cisplatin-based preoperative chemotherapy fol-
lowed by en bloc esophagectomy. By pathologic criteria,
we selected what is generally considered to be the worst co-
hort of patients with esophageal cancer undergoing surgical
therapy: those with persistent nodal disease after induction
therapy. R0 resection was achieved in 94% of these patients
with an overall and disease-free survival of 30% and 24%,
respectively. However, this remains a retrospective study
and therefore subject to inherent selection biases. Further-
more, our statistical analysis required collapsing some vari-
ables such as clinical stage and pT classification given the
small subgroup sizes. Consequently, we consider the ob-
served statistically significant variables in the model as
only hypothesis-generating, requiring confirmation in
larger, independent cohorts of similar patients.
We conclude that long-term survival can be achieved in
a meaningful proportion of patients with esophageal cancer
who have persistent nodal disease after neoadjuvant therapy.
Surgical therapy should not be withheld from this patient
population. Clinical stage, pT classification, and the number
of positive lymph nodes resected best predict survival. An
aggressive surgical approach is warranted both to accurately
stage disease and to remove residual disease. Nonregional
nodal disease does not adversely affect outcome. Postopera-
tive chemotherapy appears to confer no additional survival
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Dr Antoon E. M. R. Lerut (Leuven, Belgium). I have no finan-
cial disclosures.
This was an excellent presentation on a topic that indeed has not
been investigated thoroughly until this presentation. The conclu-
sions are first that indeed you can obtain long-term survival and dis-
ease-free survival in 1 of 4 patients. Second, patients with more
than 7 positive lymph nodes have a poor prognosis and dismal sur-
vival, and finally, adjuvant chemotherapy, at least one cycle, does
not seem to be of any benefit.The Journal of Thoracic and CaI have 2 questions. As you said, a strong negative prognostic fac-
tor is the presence of more than 7 positive nodes. However, these
data are retrieved from pathologic, that is, postoperative analysis.
The question, of course, arises whether it is possible to identify
such negative factor before surgery when reassessing the effect
of induction chemotherapy, eventually avoiding unnecessary sur-
gery in those patients. In this respect, our group some years ago
published the findings of PET scan after induction therapy, indicat-
ing that persistent positive lymph node involvement on PET scan is
a strong negative prognostic factor.
My specific question here is this: did you make such an effort to
correlate these pathologic findings of more than 7 positive nodes
with your findings obtained at baseline clinical staging and also
after restaging your patients after induction? If so, was there any
positive correlation?
Dr Stiles.That is a great question. I think everybody would like to
know how to find out who is going to do poorly. Right now, unfor-
tunately, we are not good at it. Our group has also looked at PET
scan, and we found significant improvements in survival with greater
than a 50% reduction in maximum standardized uptake value. One
point to note is that 11 of 13 patients who had a complete response
on PET in that group still had persistent disease. I think the restaging
issue works both ways. It identifies patients who have advanced dis-
ease, but some people also use it as justification not to operate based
on perceived complete response. We are not able to predict that either
with PET or with our clinical assumptions. In this patient population,
40% had improved disease or a complete response by clinical criteria;
however, they clearly did not have a complete response on pathologic
criteria. The question of determining the patient population with more
than 7 lymph nodes is a good one. We are not able to distinguish that
well on PET scan, unfortunately.
Dr Lerut. Not the exact numbers, that is correct. However, our
experience, and also, I believe, a South Korean study, showed that
if you have more than 3 individual spots on the PET scan, the prog-
nosis indeed is very dismal; as you showed, below 15.
Dr Stiles. Yes, sir.
Dr Lerut. My second question goes to the issue of the 3-field
lymphadenectomy as compared with 2-field lymphadenectomy.
What were your indications for the 2-field versus the 3-field lym-
phadenectomy? Two thirds of the patients had a 3-field and one
third a 2-field lymphadenectomy. You did not explain this. Also,
you made the point that about 30% of the patients had positive no-
des along the recurrent laryngeal nerve chain. We have to consider
the fact that this chain lies in part in the chest and in part in the neck.
Thus, the question is, what precisely was the additional yield spe-
cifically from the cervical field, in particular given the fact that it
adds to the morbidity, when adding the third field? Was there
any survival benefit from 3-field lymphadenectomy when you com-
pare it with your en bloc resection plus 2-field lymphadenectomy?
Dr Stiles. We were unable to show a survival benefit between
the 3-field and the 2-field lymphadenectomies in this patient popu-
lation. In terms of who gets it, all the patients with middle and upper
third tumors obviously get the third field, but we are a bit more se-
lective with the lower and gastroesophageal junction tumors. We
may be a bit less aggressive in patients who tend to have more co-
morbidities, particularly respiratory comorbidities, or those in
whom we are worried about recurrent nerve injury. Sometimes
with very big or obese patients, we will also be a little less likely
to pursue the third field.rdiovascular Surgery c Volume 139, Number 2 393
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SDr Lerut. Could you tell us something about the additional
yield specifically from what you found in the neck?
Dr Stiles. Dr Altorki could probably comment better. My per-
sonal take is that most of the recurrent nodes that we get are from
the chest and it is rare that we get the ones from the neck.
Dr Lerut. There are studies, mainly from Japan, showing that
a positive node at the brachiocephalic trunk is like a sentinel
node. In other words, if the nodes there are negative, it is useless
to do a cervical lymphadenectomy, because the chances of having
positive lymph nodes are below 10%, but if they are positive it is
seen as an indication to go further and do the third field. That is
why I asked that question.
Dr Stiles. Yes, sir, I agree. I think an important point to make,
though, is that a lot of these nodes in the recurrent chain can be
reached from the chest. A lot of surgeons who are doing an Ivor
Lewis procedure can get to that area and at least sample the nodes
to better stage the patients, as you suggested previously.
Dr Bryan F.Meyers (St Louis, Mo). This is a unique population
of patients, because you are picking them based on one character-
istic of their pathologic stage. You are eliminating patients who re-
ceived induction therapy and progressed on a macroscopic level
during induction therapy. You are eliminating patients who under-
went induction therapy and then had a decline in their performance
status, and you chose not to operate on them. You did not say it, but
I suspect that there are some patients who undergo exploration after
induction therapy and do not undergo resection, and those patients
also did not make it into this article. So, within the limits of the very
selected group of patients, I think you have a solid list of predictors
of poor or better outcome. However, I do not know whether it can
inform the decision about whether to operate when you suspect per-
sistent lymph nodes because that detection of persistent lymph no-
des after induction therapy is notoriously inaccurate.
The other thing I would ask you to comment on, because it is
unique, is that your induction therapy for about 20 years now has
been chemotherapy alone, and that is probably different from
most of the members of the audience. Please explain why you
started and then stuck with that regimen.
Dr Stiles. Thank you for the questions. Again, I thank both you
gentlemen for reviewing the paper on late notice.
I agree with your statement that this does not include all of those
patients. We did not capture all the patients in our database who fell
out for whatever reason, whether performance status, progression
of disease, or exploration without resection, although I think that
that number is very low. Our general point is that clearly people
can identify the patients who dramatically progress, whether the
progression is indicated by bulky lymph nodes or systemic metas-
tases. I think the issue that sometimes physicians wrestle with is
what to do if somebody gets a biopsy after induction with persistent
positive nodes, particularly if they may be celiac or recurrent laryn-
geal. Maybe we should not operate on these patients. As we have
shown, survival can be achieved in a significant portion, but, again,
it is a very selected group, a retrospective study. We tend to offer
surgery to almost everybody except for those who progress with
systemic disease or significant bulky disease in the neck.
Regarding chemotherapy versus chemoradiation, we have writ-
ten about it a lot. Everybody in the room has probably written and
read about it. To us the jury is still out on what is better, what is not.
Certainly more people experience a pCR with chemotherapy and394 The Journal of Thoracic and Cardiovascular Surgradiation therapy. Whether that translates into long-term survival,
particularly for adenocarcinoma, is unclear. I do not think that there
are good data to support that one way or another. Most patients with
this disease have systemic failure and die of systemic disease.
Therefore, to us, adding radiation therapy to the en bloc esophagec-
tomy and extensive lymphadenectomy does not add a lot to the lo-
cal treatment of this disease.
Dr Altorki. I just want to make a comment about preoperative
chemotherapy. We have learned some good lessons from preoper-
ative chemotherapy in lung cancer. I think 2 and up to 4 cycles of
chemotherapy can be given with a single-digit rate of disease pro-
gression. What I see more often is if protracted (3 or 4 months’
worth) chemoradiation is given, and then it is necessary to wait an-
other month, I tend to see more patients who progress under those
circumstances. Two to 4 cycles of chemotherapy is usually associ-
ated with very low disease progression during the treatment.
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dr Altorki, on
the basis of your data, if you identify someone in that high-risk
group, and I know you made the comment that you do not think
chemotherapy adjuvantly adds anything, but if someone has
more than 7 nodes now, what do you do? If the patients are fit,
do you think that they should be subjected to second-line or
some other cocktail?
Dr Altorki. That is a great question. I do not really know how to
pick those individuals that will be more or less than 7, if 7 is the
number. Toni mentioned 2 or 3 different areas of uptake on the
PET scan, and I would submit to you that if I ever saw that, I would
probably not operate, but that is not what you usually see. What I
try to do is restage the patients after 2 cycles, and if it seems that
they have had a favorable biological response based on the PET cri-
teria, then I add 2 additional cycles. I try to get them most of their
chemotherapy up front because I know that they are not going to be
able to take it on the back end.
DrMeyers.You said that you would restage them after 2 cycles.
Do you do endoscopic ultrasound fine needle aspiration or do you
do a PET scan?
Dr Altorki. I use PET and computed tomographic scans. I think
the data on endoscopic ultrasound and how successful fine needle
aspiration is in that setting are questionable. The PET scan is
quicker and, to my mind, even a little bit more informative.
Dr Frank C. Detterbeck (New Haven, Conn). Your survival
was quite good for those patients who have nodal disease after
esophagectomy. You do a fairly extensive lymph node dissection.
Do you think that having a few nodes positive after a very extensive
lymph node dissection is a somewhat different group of patients
than, say, if you do not do a very extensive lymph node dissection
and you have a node-positive patient? Do you think that explains
why your results are so good?
Dr Altorki. Differently stated, if I may, I think that the question
goes to what is the influence of the total lymph nodes resected on out-
come. This particular work that Brendon did does not answer that
question, because everybody had a lot of nodes resected. We have
just published in the Annals of Surgery a larger series in which there
were equal numbers of patients on each side of that divide. Clearly,
at least in our work, and I know that is not universally accepted, the
more nodes you took, the better off you were in terms of survival. If
you were truly node-negative, the difference was tiny, but if you
were node-positive, the difference was more statistically significant.ery c February 2010
